CAR-T (Autoimmune) Deal Benchmarks in Immunology & Autoimmune

Median Upfront

$914M

Range: $475M - $1.3B

Total Deal Value

$5.0B

Range: $3.1B - $6.9B

Royalty Rate

16.3% - 27.2%

Tiered up to 31.2%

Dev Milestones

$820M

Range: $527M - $1.1B

Model Your Deal

Market Analysis

CAR-T (Autoimmune) therapies in immunology & autoimmune have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 car-t (autoimmune) asset in immunology & autoimmune is $914M, with total deal values reaching $5.0B. Development milestones average $820M, while regulatory milestones contribute $1.4B.

The immunology & autoimmune car-t (autoimmune) landscape is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape. The recommended deal structure allocates approximately 18% to upfront payments and 82% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for car-t (autoimmune) immunology & autoimmune deals range from 16.3% to 27.2% at the base tier, with tiered escalation reaching 20.3%-31.2% on blockbuster sales. Commercial milestones averaging $1.8B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a car-t (autoimmune) immunology & autoimmune licensing deal?

Based on our analysis, Phase 2 car-t (autoimmune) licensing deals in immunology & autoimmune average $914M in upfront payments, with a range of $475M to $1.3B depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for car-t (autoimmune) immunology & autoimmune transactions?

The median total deal value for Phase 2 car-t (autoimmune) assets in immunology & autoimmune is $5.0B, ranging from $3.1B to $6.9B. This includes development milestones ($820M), regulatory milestones ($1.4B), and commercial milestones ($1.8B).

What royalty rates are standard for car-t (autoimmune) deals in immunology & autoimmune?

Base royalty rates for car-t (autoimmune) immunology & autoimmune transactions range from 16.3% to 27.2%, with tiered escalations reaching 20.3%-31.2% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in car-t (autoimmune) immunology & autoimmune deals?

CAR-T (Autoimmune) immunology & autoimmune deals allocate approximately 82% of total deal value to milestones. Development milestones ($820M) make up the largest share, followed by commercial milestones ($1.8B) and regulatory milestones ($1.4B).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Immunology & Autoimmune

View

Monoclonal Antibody in Immunology & Autoimmune

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included